SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-309500
Filing Date
2022-12-21
Accepted
2022-12-21 06:08:03
Documents
13
Period of Report
2022-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d439272d8k.htm   iXBRL 8-K 40923
2 EX-2.1 d439272dex21.htm EX-2.1 14734
  Complete submission text file 0001193125-22-309500.txt   183124

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fstx-20221220.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20221220_lab.xml EX-101.LAB 17169
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20221220_pre.xml EX-101.PRE 10788
7 EXTRACTED XBRL INSTANCE DOCUMENT d439272d8k_htm.xml XML 3223
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 221476453
SIC: 2834 Pharmaceutical Preparations